Ionis Pharmaceuticals IONS Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's debt securities, available-for-sale, continuous unrealized loss position, 12 months or longer, accumulated loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's debt securities, available-for-sale, continuous unrealized loss position, 12 months or longer, accumulated loss?
- Ionis Pharmaceuticals (IONS) reported debt securities, available-for-sale, continuous unrealized loss position, 12 months or longer, accumulated loss of $25K in Q1 2026.
- How has Ionis Pharmaceuticals's debt securities, available-for-sale, continuous unrealized loss position, 12 months or longer, accumulated loss changed year-over-year?
- Ionis Pharmaceuticals's debt securities, available-for-sale, continuous unrealized loss position, 12 months or longer, accumulated loss decreased by 67.1% year-over-year, from $76K to $25K.